The antibody-drug conjugates (ADCs) market is at the forefront of innovation in cancer treatment, merging the precision of targeted therapy with the potency of chemotherapy. Valued at USD 7.96 billion in 2023, this market is poised to grow at an impressive CAGR of 17.1% over the forecast period, reaching a staggering USD 32.97 billion by 2032. This growth reflects the increasing awareness of...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek